Evidence map›Paper›PMID 37662380›Full record

ArticlebioRxiv : the preprint server for biology2023

Sphingosine 1-phosphate receptor 1 inhibition induces a pro-apoptotic signaling cascade in T cells.

Dhaval Dixit, Victoria M Hallisey, Ethan Y S Zhu, Martyna Okuniewska, Ken Cadwell, Jerry E Chipuk, Jordan E Axelrad, Susan R Schwab

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Dhaval Dixit
Victoria M Hallisey
Ethan Y S Zhu
Martyna Okuniewska
Ken Cadwell
Jordan E Axelrad
Susan R Schwab
New York University · USIcahn School of Medicine at Mount Sinai · USUniversity of Pennsylvania · US

Funding

The role of SPNS2 in T cell responsesR01AI085166 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Susan Ruth Schwab · 2011 to 2026
$6.5M
Training Program in Immunology and Inflammation.T32AI100853 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Susan Ruth Schwab · 2012 to 2026
$4.5M
Chronic Mitochondrial Division and Melanoma: Mechanism, Prognosis, and TherapyR01CA267696 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jerry Edward Chipuk · 2022 to 2026
$2.4M
The Oncogene Activated Mitochondrial Unfolded Protein Response Regulates Senescence BiologyR01CA271346 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Jerry Edward Chipuk · 2023 to 2026
$2.4M
Function and Regulation of the BCL-2 FamilyR01CA237264 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHIPUK, JERRY EDWARD · 2020 to 2024
$1.9M
A map of sphingosine 1-phosphate distributionR01AI123308 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHWAB, SUSAN RUTH · 2017 to 2020
$1.7M
NCI NIH HHS R01 CA237264NCI NIH HHS R01 CA267696NCI NIH HHS R01 CA271346NIAID NIH HHS R01 AI085166NIAID NIH HHS R01 AI123308NIAID NIH HHS T32 AI100853
6 · The paper itself

Abstract

Effective immunity requires a large, diverse naïve T cell repertoire circulating among lymphoid organs in search of antigen. Sphingosine 1-phosphate (S1P) and its receptor S1PR1 contribute by both directing T cell migration and supporting T cell survival. Here, we address how S1P enables T cell survival, and the implications for patients treated with S1PR1 antagonists. Contrary to expectations, we found that S1PR1 limits apoptosis by maintaining the appropriate balance of BCL2 family members via restraint of JNK activity. Interestingly, the same residues of S1PR1 that enable receptor internalization are required to prevent this pro-apoptotic cascade. Findings in mice were recapitulated in ulcerative colitis patients treated with the S1PR1 antagonist ozanimod, and the loss of naïve T cells limited B cell responses. Our findings highlight an unexpected effect of S1PR1 antagonists on the ability to mount immune responses within lymph nodes, beyond their effect on lymph node egress, and suggest both limitations and novel uses of this important class of drugs.

Identifiers

PMID37662380
PMCPMC10473648
OpenAlexW4386070164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.